만성 질환의 유병률 증가와 고령화가 대상포진 백신 시장 수요를 주도하고 있습니다. 또한, 대상포진 백신은 수두 대상포진 바이러스에 의한 대상포진 예방에 도움이 되는 백신 접종의 중요성에 대한 인식이 높아지면서 2024년 16억 2,000만 달러의 매출을 넘어 2032년까지 34억 7,000만 달러에 달할 것으로 예측됩니다.
또한, 백신 기술의 발전과 보다 효과적인 새로운 백신의 개발은 대상포진 백신 시장의 성장을 가속할 것으로 예측됩니다. 선진국의 헬스케어 정책 시행이 증가함에 따라 2026년부터 2032년까지 약 10%의 연평균 복합 성장률(CAGR)로 시장 성장이 가능할 것으로 예측됩니다.
대상포진 백신 시장 정의/개요
대상포진 백신은 일반적으로 대상포진 백신이라고 불리며, 수두의 원인인 수두 대상포진 바이러스의 재활성화에 의해 유발되는 대상포진에 대한 중요한 예방 수단입니다. 이 백신에는 약독화된 바이러스가 포함되어 있어 면역체계를 자극하여 항체를 생성하여 대상포진을 예방하고 심각성을 감소시킬 수 있습니다. 이 백신의 주요 용도는 연령에 따른 면역력 저하로 인해 대상포진에 걸릴 위험이 높아지는 50세 이상에서 대상포진을 예방하는 것입니다. 또한, 대상포진으로 인한 만성 통증, 신경학적 문제 등 대상포진으로 인한 합병증을 완화하는 데에도 도움이 됩니다.
현재 사용 가능한 대상포진 백신은 주로 Shingrix와 Zostavax 두 가지가 있으며, 향후 더 넓은 범위에서 더 효과적인 선택지를 찾기 위한 연구가 진행되고 있습니다. 전 세계 대상포진 관련 질환의 부담을 줄이기 위해, 특히 중저소득 국가에서 대상포진 백신의 접근성을 강화하기 위한 노력이 진행되고 있습니다.
대상포진 유병률은 고령화, 면역력 저하, 암 및 HIV와 같은 만성 질환의 유병률 증가 등의 요인으로 인해 전 세계적으로 증가하고 있으며, 이는 대상포진 백신 시장의 성장을 가속하고 있습니다.
그 결과, 대상포진을 예방하기 위한 백신 접종의 중요성을 인식하는 사람들이 늘어나면서 대상포진 백신에 대한 수요는 향후 몇 년 동안 증가할 가능성이 높습니다. 이는 대상포진 백신 시장 성장에 큰 기회가 될 것입니다. 예를 들어, 2023년 4월 25일 GSK는 대상포진 백신(대상포진)을 출시했는데, GSK에 따르면 이 백신의 효능은 90%이며, 대상포진에 대해 최소 10년간 예방 효과가 있다고 합니다.
대상포진을 예방하기 위한 백신 접종의 중요성에 대한 인식이 높아지면서 대상포진 백신 시장 수요를 견인하고 있습니다. 고령자는 대상포진에 걸리기 쉽기 때문에 전 세계 고령화도 시장 성장에 기여하고 있습니다. 예를 들어, 인도인을 대상으로 한 혈청 유병률 조사에 따르면, 40세까지 대상포진 바이러스를 보유하고 있는 사람이 90% 이상이며, 대상포진에 걸리기 쉬운 것으로 나타났습니다. 대상포진 및 대상포진 후 신경통 예방을 위해 50세 이상의 성인에게 신플로릭스 백신이 승인되었습니다.
또한, 백신 기술의 발전과 보다 효과적인 새로운 백신의 개발은 시장 성장을 가속할 것으로 예측됩니다. 이러한 모든 요인으로 인해 대상포진 백신 시장은 향후 몇 년 동안 안정적인 성장세를 보일 것으로 예측됩니다.
대상포진 백신의 고비용은 특히 저소득 국가의 많은 사람들에게 큰 장벽이 되어 대상포진 백신 시장의 성장을 저해할 수 있습니다. 이러한 비용 장벽은 연구개발의 복잡성, 제조 공정, 유통 물류, 효과적인 면역을 보장하기 위해 여러 번 접종해야 하는 등 다양한 요인에 기인합니다.
또한, 의료 서비스 제공업체와 의료기관은 대상포진 백신과 같은 고가의 백신을 구매할 때, 특히 낮은 환급률로 인해 재정적 제약에 직면할 수 있습니다. 이는 백신 접종에 대한 접근성을 더욱 제한하고 전반적인 수요를 감소시켜 시장 성장을 제한할 수 있습니다.
엄격한 규제에 대한 인식 증가는 대상포진 백신 시장의 성장에 도전이 될 수 있습니다. 백신 승인 절차는 시간과 비용이 많이 소요되기 때문에 새로운 백신의 출시가 늦어지고, 백신 접근성이 제한될 수 있습니다. 또한, 안전성과 유효성에 대한 엄격한 규제 요건은 신규 제조업체 시장 진입을 어렵게 만들 수 있습니다.
또한, 백신으로 인한 발진 증가는 대상포진 백신 시장의 성장을 저해할 수 있습니다. 백신 접종 후 발진과 같은 부작용이 발생하면 백신에 대한 신뢰가 떨어지고 수요가 감소할 수 있습니다. 이는 궁극적으로 시장 성장에 영향을 미칠 수 있습니다.
The rising prevalence of chronic diseases and the aging population are driving the demand for zoster vaccine market. Additionally, the zoster vaccine can be attributed to the increasing awareness regarding the importance of vaccination in helping to prevent shingles caused by the varicella-zoster virus is anticipated to fuel the market to surpass revenue of USD 1.62 Billion valued in 2024 and reach USD 3.47 Billion by 2032.
Also, growing advancements in vaccine technology and the development of new and more effective vaccines are also expected to propel the growth of the zoster vaccine market. The increasing implementation of healthcare policies in developed nations is enabling the market grow at a CAGR of about 10% from 2026 to 2032.
Zoster Vaccine Market: Definition/ Overview
The zoster vaccine, commonly referred to as the shingles vaccine, is a crucial preventive measure against herpes zoster, an ailment triggered by the reactivation of the varicella-zoster virus, which also causes chickenpox. This vaccine contains a weakened form of the virus, stimulating the immune system to produce antibodies that can prevent or mitigate the severity of shingles. Its primary application lies in preventing shingles in individuals aged 50 and older, who are at an increased risk due to age-related decline in immunity. Additionally, the vaccine helps in reducing complications associated with shingles, such as chronic pain and neurological issues.
Currently, there are two main types of zoster vaccines available that are Shingrix and Zostavax and future research is exploring even more effective options with broader applications. The Protection and require fewer doses, potential expansion of recommendations to include younger age groups or those with specific medical conditions, exploration of combination vaccines for simplified immunization schedules, and efforts to enhance global access, particularly in low- and middle-income countries, to alleviate the burden of shingles-related illness on a global scale.
The prevalence of herpes zoster disease is rising globally due to factors such as the aging population, weakened immune systems, and increased prevalence of chronic diseases such as cancer and HIV will drive the growth of the zoster vaccine market
As a result, the demand for zoster vaccine is likely to increase in the coming years as more people become aware of the importance of vaccination to prevent shingles. This presents a significant opportunity for the growth of the zoster vaccine market. For instance, on 25 April 2023, GSK launched the shingles vaccine, (herpes zoster). GSK said the vaccine had 90% efficacy and provided at least 10 years of protection against herpes zoster.
The growing awareness among people about the importance of vaccination to prevent shingles is driving the demand for the zoster vaccine market. The aging population worldwide is also contributing to the growth of the market as older adults are more susceptible to shingles. For instance, according seroprevalence study in Indian subjects showed that by the age of 40 years, more than 90% of the participants had this virus in their bodies and were therefore vulnerable to shingles. For the prevention of shingles and post-herpetic neuralgia, Shingrix vaccine has been approved for adults above 50 years.
Furthermore, advancements in vaccine technology and the development of new and more effective vaccines are expected to boost the growth of the market. All these factors suggest that the zoster vaccine market is poised for steady growth in the coming years.
Increasing the high cost of the zoster vaccine can be a significant barrier for many people, especially in low-income countries, and it could potentially hamper the growth of the zoster vaccine market. This cost barrier stems from various factors, including the complexities of research and development, manufacturing processes, distribution logistics, and the necessity for multiple doses to ensure effective immunity.
Additionally, healthcare providers and institutions may face financial constraints in purchasing high-cost vaccines like the zoster vaccine, particularly in settings where reimbursement rates are inadequate. This can further limit access to vaccination and reduce overall demand, constraining market growth.
Growing awareness of stringent regulations can indeed pose a challenge to the growth of the zoster vaccine market. The regulatory approval process for vaccines can be lengthy and costly, which can delay the launch of new vaccines and limit their availability. Additionally, regulatory requirements for safety and efficacy can be strict, which can make it difficult for new manufacturers to enter the market.
Furthermore, the increasing occurrence of vaccine rashes can indeed hinder the growth of the zoster vaccine market. When people experience rashes or other adverse reactions after receiving a vaccine, it can lead to a decrease in confidence in the vaccine and reduce demand for it. This can ultimately impact the growth of the market.
The rising use of the Shingrix vaccine is expected to drive the zoster vaccine market. Shingrix is a highly effective vaccine for preventing zoster, and it has been shown to provide longer-lasting protection than other available vaccines. This vaccine provides a high level of immunity for at least 7 years after vaccination, as more people become aware of the benefits of Shingrix the demand for the vaccine is expected to increase, which will help to drive growth in the zoster vaccine market.
Additionally, during the forecast period, there will be a rise in demand for these vaccinations due to increasing awareness of the disease's effects and the growing number of countries that have approved Shingrix for use as a vaccine. For instance, GSK announced the shingles vaccine Shingrix in India. This vaccine is recommended for people aged 50 years and above to protect against shingles.
Increasing awareness of the importance of shingles vaccination will drive the zoster vaccine market Companies may invest in marketing efforts to differentiate their products and highlight their efficacy and safety profiles. Additionally, the drive for innovation may lead to the development of new vaccine formulations or delivery methods to better meet the needs of consumers.
The surge in demand for shingles vaccines propels market expansion, prompting vaccine manufacturers to bolster production capacities to satisfy healthcare providers and consumer requirements. This heightened production not only addresses immediate demand but also fosters increased investment in research and development. As revenue streams grow, manufacturers allocate more resources to R&D endeavors, aiming to enhance vaccine efficacy, safety, and accessibility
Increasing demand for technological developments in vaccine formulation, delivery, and production are improving the accessibility, safety, and efficacy of vaccinations. This accelerates the market's growth for zoster vaccines, providing better preventive treatments and enhanced public health results.
Recombinant vaccines are produced using genetic engineering techniques, which allows for more precise targeting of the virus or bacteria being targeted. This technology has been used to develop new vaccines, including the Shingrix vaccine for shingles. The growing use of recombinant vaccines offers several advantages over traditional vaccines, including improved safety, efficacy, and ease of production. As a result, they are becoming increasingly popular among healthcare providers and patients. This vaccine contains purified parts of pathogen that are antigenic, or necessary to elicit a protective immune response.
In addition to the benefits of recombinant vaccines, other factors such as the aging population, increasing healthcare expenditure, and rising awareness regarding the importance of preventive healthcare are expected to contribute to the growth of the zoster vaccine market. Aging comes with several health problems such as a weak immune system, which make the old population susceptible to infections like shingles. The increasing geriatric population globally estimated at 3 to 5 cases per 1000 individuals annually is contributing to the growth of the zoster vaccine market and is expected to continue its growth throughout the forecast period.
Country/Region-wise
The rising prevalence of chickenpox in North America boost the zoster vaccine market. Chickenpox and shingles are caused by the same virus, known as the varicella-zoster virus. While chickenpox is a common childhood illness, the virus can remain dormant in the body and reactivate later in life as shingles. Additionally, recommendations for shingles vaccine may be part of the public health response to chickenpox outbreaks, especially for those who are more susceptible due to age or underlying medical issues. For Instance, on 7 September 2022, 21,060 cases of chickenpox were recorded by Mexican health authorities (11,057 males and 10,003 women). This is a significantly higher number than the 8,897 cases reported in 2021, a 137% rise. The likelihood of developing shingles is increased by the high prevalence of chickenpox.
The rising healthcare expenditure in North America has led to a surge in demand for the Zoster vaccine, thereby driving the growth of the market. This vaccine is highly effective in preventing shingles, which is a painful skin rash caused by the reactivation of the varicella-zoster virus.
Rising awareness regarding preventive healthcare will drive the zoster vaccine market. Public health campaigns and a growing focus on preventative measures are making people more aware of the importance of proactive healthcare. This shift in perspective is leading to a greater willingness to get vaccinated against diseases like shingles. People are becoming more informed about the potential complications of shingles, such as PHN, and understand the value of vaccination in preventing this debilitating condition. This growing awareness will likely lead to a significant increase in the demand for zoster vaccines in the coming years.
Growing awareness of government vaccine programs in the Asia-Pacific region is expected to drive the demand for zoster vaccines and contribute to the growth of the market. Many governments in the region have launched vaccination programs to prevent various diseases, including shingles. These programs aim to increase awareness about vaccination and make vaccines more accessible to the population, especially older adults who are more susceptible to shingles.
For example, in Japan, the government has included the zoster vaccine in its national vaccination program for older adults, which covers the cost of the vaccine for eligible individuals. Additionally, in India, the government has launched various vaccination programs to prevent diseases such as hepatitis, influenza, and pneumococcal disease, which are also expected to increase awareness about the importance of vaccination and drive the demand for zoster vaccine.
Changing lifestyles in Asia-Pacific are expected to drive the zoster vaccine market. As people in the region become more health-conscious and adopt healthier lifestyles, the risk of developing shingles may decrease. However, the demand for zoster vaccine is still expected to increase as people become more aware of the importance of vaccination and take preventive measures to protect themselves against the disease.
Furthermore, government initiatives are expected to boost the growth of the market and encourage more manufacturers to invest in the development of new and more effective vaccines for shingles.
The zoster vaccine market, while experiencing promising growth, is a concentrated landscape with a few key players vying for dominance. The zoster vaccine market is dynamic and competitive and will benefit public health. It can lead to the development of more effective, accessible, and affordable vaccines, offering broader protection against shingles and its debilitating complications. The interplay between established players, innovative newcomers, and regulatory bodies will define the future of the zoster vaccine market.
Some of the prominent players operating in the zoster vaccine market include: